Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7373
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Epigenetic preconditioning with decitabine sensitizes glioblastoma to temozolomide via induction of MLH1 ; volume:147 ; number:3 ; day:19 ; month:3 ; year:2020 ; pages:557-566 ; date:5.2020
Journal of neuro-oncology ; 147, Heft 3 (19.3.2020), 557-566, 5.2020
- Creator
-
Gallitto, Matthew
Cheng He, Rossana
Inocencio, Julio F.
Wang, Huaien
Zhang, Yizhou
Deikus, Gintaras
Wasserman, Isaac
Strahl, Maya
Smith, Melissa
Sebra, Robert
Yong, Raymund L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11060-020-03461-4
- URN
-
urn:nbn:de:101:1-2020080123420640005705
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gallitto, Matthew
- Cheng He, Rossana
- Inocencio, Julio F.
- Wang, Huaien
- Zhang, Yizhou
- Deikus, Gintaras
- Wasserman, Isaac
- Strahl, Maya
- Smith, Melissa
- Sebra, Robert
- Yong, Raymund L.
- SpringerLink (Online service)
Other Objects (12)
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron Retention
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide
Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron Retention
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide
Knockdown of the TP53-induced glycolysis and apoptosis regulator (TIGAR) sensitizes glioma cells to hypoxia, irradiation and temozolomide
The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment
Inhibition of gap junctions sensitizes primary glioblastoma cells for temozolomide
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2‐Mediated MLH1 Intron Retention
Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)
BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)
Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1–Survivin axis
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide